ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2215 • ACR Convergence 2022

    Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis

    Daniel Solomon1, Jon Giles2, Katherine Liao1, Paul Ridker1, Pamela Rist1, Robert Glynn1, Rachel Broderick3, Fengxin Lu1, Meredith Murray1, Kathleen Vanni1, Leah Santacroce1, Shady Abohashem4, Philip Robson5, Zahi Fayad6, Venkatesh Mani5, Ahmed Tawakol4 and Joan Bathon7, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Columbia University, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Icahn School of Medicine at Mount Sinai, New York, NY, 6Mount Sinai, New York, NY, 7Columbia University Medical Center, New York, NY

    Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
  • Abstract Number: 2219 • ACR Convergence 2022

    Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

    Beth Wallace1, Yuqing Gao2, H. Myra Kim3, Punyasha Roul4, Ted Mikuls5, Daniel Clauw6, Bryant England7, Joshua Baker8, Brian Sauer9, Grant Cannon10, Shirley Cohen-Mekelberg1, Wyndy Wiitala2, Jeremy Sussman1, Rodney Hayward1 and Akbar Waljee1, 1University of Michigan Department of Internal Medicine; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 2Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3Center for Statistical Consultation and Research, University of Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare Center, Ann Arbor, MI, 4UNMC, Omaha, NE, 5Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6University of Michigan Department of Anesthesia, Ann Arbor, MI, 7University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA, 9Salt Lake City VA/University of Utah, Salt Lake City, UT, 10Retired, Salt Lake City, UT

    Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) at some point to manage RA symptoms. Prior work suggests recent GC use is associated with major…
  • Abstract Number: 2220 • ACR Convergence 2022

    Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study

    YoungEun Kim1, Ye-Jee Kim2, Seonok Kim2, Soo Min Ahn1, Ji Seon Oh3, Yong Gil Kim1, Chang Keun Lee1, Bin Yoo1, Sang Hyoung Park4 and Seokchan Hong1, 1Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 2Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 3Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea, 4Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea

    Background/Purpose: Janus kinase (JAK) inhibitors are known to increase the risk of herpes zoster (HZ) reactivation; however, studies on the risk of HZ recurrence when…
  • Abstract Number: 2214 • ACR Convergence 2022

    Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)

    Christopher Redmond1, Moses Kitakule2, Riccardo Castagnoli3, Francesco Licciardi4, Cihan Oguz5, Maria Cecilia Poli6, Aran Son5, Sarah Weber5, Luigi Notarangelo7, Helen Su8 and Daniella Schwartz9, 1National Institutes of Health, Rockville, MD, 2Columbia University, New York, NY, 3National Institute of Allergy and Infectious Diseases, Bethesda, MD, 4OSPEDALE REGINA MARGHERITA, Torino, Italy, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6Roberto del Rio, Santiago, Chile, 7NIAID/NIH, Bethesda, MD, 8NIH/NIAID, Bethesda, MD, 9National Institutes of Health Clinical Center, Bethesda, MD

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable…
  • Abstract Number: 2096 • ACR Convergence 2022

    Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus

    Marcela Muñoz Urbano1, Diana C. Quintero-González1, Mauricio Rojas2, Joaquín Rodelo1, Alba Luz León Álvarez1, Luis Gonzalez1 and Gloria Vásquez3, 1Universidad de Antioquia, Medellín, Colombia, 2Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, 3Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia

    Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
  • Abstract Number: 2160 • ACR Convergence 2022

    The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients

    Henriette Didriksen1, Øyvind Molberg2, Adi Mehta3, Suzana Jordan4, Håvard Fretheim3, Einar Gude3, Thor Ueland3, Cathrine Brunborg3, Vyacheslav Palchevskiy5, Torhild Garen3, Øyvind Midtvedt3, Arne Andreassen3, Fridtjof Lund-Johansen3, Oliver Distler4, John Belperio5 and Anna-Maria Hoffmann-Vold3, 1Oslo University Hospital, Moss, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
  • Abstract Number: 2206 • ACR Convergence 2022

    Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

    Lihi Eder1, Fangya Ma2, Josefina Marin3, Minna Kohler4, Janeth Yinh5, Ari Polachek6, Marcos Rosemffet7, Ernesto Rodriguez8, Ilaria Tinnazzi9, Amir Haddad10, Philippe Carron11, Mariana Alves Ferreira Martins12, Catherine Bakewell13, Fahmeen J. Afgani14, Richard Cook2, Sibel Aydin15 and Gurjit S. Kaeley16, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Tel Aviv Medical Center, Tel Aviv, Israel, 7Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 8Florida Medical Clinic, Tampa, FL, 9Ospedale Sacro Cuore-Don Calabria, Negrar, Italy, 10Carmel Medical Centre, Haifa, Israel, 11Ghent University Hospital, Ghent, Belgium, 12São José Do Rio Preto Medical School, São José do Rio Preto, Brazil, 13Intermountain Healthcare, Salt Lake City, UT, 14Women's College Hospital, Toronto, ON, Canada, 15University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, 16UF COM-J, Ponte Vedra Beach, FL

    Background/Purpose: Variability in scoring of sonographic entheseal lesions may be influenced by patient characteristics and sonographer expertise. We aimed to assess inter-rater agreement in scoring…
  • Abstract Number: 2031 • ACR Convergence 2022

    Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

    Dong Xu1, Shangzhu Zhang1, Cibo Huang2, Chenghui Huang3, Li Qin4, Xiaomei Li5, Meiqing Chen6, Xiumei Liu7, Yi Liu8, Zhijun Li9, Jiankang Hu10, Chunde Bao11, wei Wei12, Jing Tian13, Xinwang Duan14, Jianmin Fang15 and Xiaofeng Zeng16, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Beijing Hospital, Beijing, China, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Huzhou Third Municipal Hospital, Huzhou, China, 5Anhui Provincial Hospital, Hefei, China, 6The First Affiliated Hospital of Xiamen University, Xiamen, China, 7The First Hospital of Shanxi Medical University, Taiyuan, China, 8West China Hospital of Sichuan University, Chengdu, China, 9The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 10Jiangxi Pingxiang People’s Hospital, Shanghai, China, 11Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 12Tianjin Medical University General Hospital, Tianjin, China, 13Second Xiangya Hospital of Central South University, Changsha, China, 14The Second Affiliated Hospital of Nanchang University, Nanchang, China, 15Shanghai Tongji Hospital, Shanghai, China, 16Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
  • Abstract Number: 1751 • ACR Convergence 2022

    Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

    Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA

    Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
  • Abstract Number: 2193 • ACR Convergence 2022

    Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry

    Simon Galmiche1, Benjamin Thoreau2, Stéphane Bretagne3, Alexandre Alanio3, André Paugam4, Valérie Bru5, Sophie Cassaing6, Jean-Pierre Gangneux7, Hélène Guégan7, Loïc Favennec8, Alida Minoza9, Florent Morio10, Julie Bonhomme11, Guillaume Desoubeaux12, Odile Eloy13, Lilia Hasseine14, Milène Sasso15, Laurence Millon16, Anne-Pauline Bellanger16, Philippe Poirier17, Maxime Moniot17, Taieb Chouaki18, Antoine Huguenin19, Frédéric Dalle20, Bernard Bouteille21, Muriel Nicolas22, Nicole Desbois-Nogard23, Marie-Elisabeth Bougnoux24, François Danion25, Vincent Poindron26, Antoine Néel27, Karine Boukris-Sitbon28, Fanny Lanternier29 and Benjamin Terrier30, 1Institut Pasteur, Paris, France, 2AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, 3Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, 4Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, 5Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, 6Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, 7Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, 8French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, 9Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, 10Parasitologe – Mycologie, CHU de Nantes, Nantes, France, 11Microbiologie, CHU de Caen, Caen, France, 12Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, 13Microbiologie, Hôpital de Versailles, Le Chesnay, France, 14Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, 15Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, 16Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, 17Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, 18Mycologie – parasitologie, CHU d’Amiens, Amiens, France, 19Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, 20Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, 21Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, 22Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, 23Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, 24Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, 25Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 26Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 27CHU de Nantes, Nantes, France, 28Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, 29Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, 30National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

    Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
  • Abstract Number: 2217 • ACR Convergence 2022

    Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

    Amir Razmjou1, Jennifer Wang1, Ani Shahbazian1, Jeffrey Curtis2, Dimitrios Pappas3, Joel Kremer4 and Christina Charles-Schoeman5, 1UCLA Medical Center, Los Angeles, CA, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation, Delray Beach, FL, 5Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

    Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
  • Abstract Number: 2202 • ACR Convergence 2022

    Association of Visit-based Retention and Receipt of Serologic Testing with Acute Care Use Among Young Adults with Lupus: A Medicare Cohort Study

    Maria Schletzbaum1, Brad C. Astor2, W. Ryan Powell3, Shivani Garg4, Andrea Gilmore-Bykovskyi5, Joseph A. Kramer6, Amy J. Kind7 and Christie Bartels8, 1University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Middleton, WI, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Nephrology Division and Department of Population Sciences, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, 4University of Madison, School of Medicine and Public Health, Madison, WI, 5University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, 6University of Wisconsin School of Medicine and Public Health, Department of Medicine & Center for Health Disparities Research,, Madison, WI, 7University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, 8University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: While high quality lupus care is associated with less damage, the impact of care use patterns and care quality on lupus outcomes remains unclear,…
  • Abstract Number: 2170 • ACR Convergence 2022

    Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis

    Francesco Del Galdo1, Suiyuan Huang2, Lesley-Anne Bissell3, sindhu johnson4, Daniel Furst5 and Dinesh Khanna6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, 2University of Michigan, Ann Arbor, MI, 3University of Leeds, Leeds, United Kingdom, 4Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5University of California Los Angeles, Los Angeles, CA, 6Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
  • Abstract Number: 2109 • ACR Convergence 2022

    Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Arthur Kavanaugh1, Gordon Lam2, Lai-shan Tam3, Natalie Shiff4, Youngja Lee5, Ana-Maria Bravo Perdomo6, May Shawi7, Elizabeth Hsia8, Emmanouil Rampakakis9 and Carlos Enrique Toro Gutiérrez10, 1University of California San Diego, La Jolla, CA, 2Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, 5Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, 6Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, 9McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 10Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia

    Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
  • Abstract Number: 2041 • ACR Convergence 2022

    Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome

    SABA NAYAR1, Jason D. turner1, Saba Asam1, Charlotte G. Smith1, Serena Colfrancesco2, Ana Teodósio1, Joe Flint1, David H Gardner1, Professor Simon Bowman3, Adam Croft1, Andrew Filer1, Benjamin A. Fisher1, Christopher Buckley4 and Francesca Barone5, 1University of Birmingham, Birmingham, United Kingdom, 2University of Rome, Rome, Italy, 3University Hospitals Birmingham, Birmingham, United Kingdom, 4University of Oxford, Oxford, United Kingdom, 5University of Birmingham, Needham, MA

    Background/Purpose: Sjögren's syndrome (SjS) shares a series of symptoms with non-SjS Sicca syndrome, a salivary gland disease characterised by glandular dysfunction and dryness. However, unlike…
  • « Previous Page
  • 1
  • …
  • 430
  • 431
  • 432
  • 433
  • 434
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology